▎药明康德内容团队编辑优时比（UCB）今天宣布，美国FDA已批准Bimzelx（bimekizumab）用于治疗中度至重度化脓性汗腺炎（HS）成人患者。根据新闻稿，Bimzelx是可同时选择性抑制白介素17A（IL-17A）和白介素17F（IL-17 ...

全球生物制药公司UCB于11月20日宣布，美国食品药品监督管理局 (FDA)批准Bimzelx (bimekizumab-bkzx，比美吉珠单抗)用于治疗中度至重度化脓性汗腺炎 ...

This approval is the fifth overall for bimekizumab (Bimzelyx; UCB Pharma) in the US, and they all have come in the last 13 ...

The US Food and Drug Administration has approved bimekizumab, a humanized interleukin (IL)-17A and IL-17F antagonist, for the ...

The Food and Drug Administration (FDA) has approved Bimzelx ® (bimekizumab-bkzx) for the treatment of moderate to severe hidradenitis suppurativa (HS) in adults.

The novel IL-17A and IL-17F inhibitor has been approved for moderate to severe hidradenitis suppurativa, a chronic and ...

A trio of abstracts presented at ACR Convergence 2024, the annual meeting of the American College of Rheumatology, bear out the benefits of bimekizumab (Bimzelx; UCB Pharma) for use against active ...

FDA approves UCB's Bimzelx for adults with moderate to severe hidradenitis suppurativa, supported by Phase 3 trials showing significant symptom improvement.

Bimekizumab was associated with clinically meaningful improvements in HS signs and symptoms compared with placebo. The Food and Drug Administration (FDA) has approved Bimzelx ® (bimekizumab-bkzx ...

The first phase 3 data with UCB’s key pipeline drug bimekizumab show that it hit all its efficacy targets in psoriasis – and performed better than Johnson & Johnson’s blockbuster rival Stelara.

The U.S. FDA added hidradenitis suppurativa to the label for UCB SA’s Bimzelx (bimekizumab-bkzx), throwing renewed light on the indication, a chronic disease that causes painful, boil-like lumps that ...